Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Schroeder (1952)
The Effect of 1‐Hydrazinophthalazine in HypertensionCirculation, 5
K. Grimson, E. Orgain, C. Rowe, H. Sieber (1952)
Caution with regard to use of hexamethonium and "apresoline".Journal of the American Medical Association, 149 3
F. Smirk (1953)
Action of a new methonium compound in arterial hypertension; pentamethylene 1 : 5-bis-n-(n-methyl-pyrrolidinium) bitartrate (M. & B. 2050A).Lancet, 1 6758
K. Grimson, Antone Tarazi, Joe Frazer (1955)
A New Orally Active Quaternary Ammonium, Ganglion Blocking Drug Capable of Reducing Blood Pressure, SU‐3088Circulation, 11
E. Freis, E. Partenope, L. Lilienfield, J. Rose (1954)
A Clinical Appraisal of Pentapyrrolidinium (M&B 2050) in Hypertensive PatientsCirculation, 9
A. Corcoran, H. Dustan, R. Taylor, I. Page (1954)
Management of hypertensive disease.The American journal of medicine, 17 3
J. Currens, G. Myers, P. White (1953)
The use of protoveratrine in the treatment of hypertensive vascular disease.American heart journal, 46 4
K. Grimson, E. Orgain, Banks Aderson, G. D'angelo (1953)
Total Thoracic and partial to total Lumbar Sympathectomy, Splanchnicectomy and Celiac Ganglionectomy for HypertensionAnnals of Surgery, 138
R. Maxwell, A. Campbell (1953)
New sympathicolytic agents.Lancet, 1 6758
H. Schroeder (1952)
Control of hypertension by hexamethonium and 1-hydrazinophthalazine; preliminary observations.A.M.A. archives of internal medicine, 89 4
R. Taylor, H. Dustan, A. Corcoran, I. Page (1952)
Evaluation of l-hydrazinophthalazine (apresoline) in treatment of hypertensive disease.A.M.A. archives of internal medicine, 90 6
J. Moyer, S. Miller, R. Ford (1953)
Orally administered hexamethonium chloride in hypertension.Journal of the American Medical Association, 152 12
R. Gifford, E. Allen, N. Birkhead (1954)
Pentapyrrolidinium bitartrate (M. & B. 2050A) in the treatment of hypertension; preliminary observations.Proceedings of the staff meetings. Mayo Clinic, 29 18
R. Wilkins (1952)
New drug therapies in arterial hypertension.Annals of internal medicine, 37 6
During the last five years several drugs have been introduced for the treatment of hypertension. Of these, hexamethonium, pentolinium tartrate (Ansolysen), and Ecolid [4, 5, 6, 7-tetrachloro-2-(2-dimethylaminoethyl) isoindoline dimethochloride], which was known experimentally as Su 3088, are orally active agents that reduce blood pressure by blocking or suppressing cholinergic nerve transmission through the sympathetic and parasympathetic ganglions. Hydralazine (Apresoline) hydrochloride has a moderate adrenolytic or sympatholytic action. There is some evidence that it increases renal blood flow, depresses the midbrain, or neutralizes certain humoral vasopressor substances. Alkavervir (Veriloid) and protoveratrines A and B (Veralba), alkaloids of Veratrum viride and Veratrum album, respectively, induce dilatation of arterioles by acting on vasomotor centers or influencing the receptors of the buffer nerves. The Veratrum drugs slow the heart rate and in larger doses cause nausea and then vomiting and salivation. Rauwolfia serpentina, its purified fraction, alseroxylon, or its crystalline alkaloid, reserpine, have a
JAMA – American Medical Association
Published: Jun 4, 1955
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.